A microchip implanted in tumors could reveal which drugs work best

NCT ID NCT04045470

Recruiting now Diagnosis Sponsor: Dana-Farber Cancer Institute Source: ClinicalTrials.gov ↗

First seen Jul 27, 2026 · Last updated Jul 28, 2026 · Updated 1 time

Summary

This pilot study tests a small microdevice that is temporarily placed inside a skin lesion to release up to 19 different cancer drugs at once. The goal is to see if the device can safely and effectively show which drugs kill the cancer cells in that specific patient. The study involves people with cutaneous T-cell lymphoma or peripheral T-cell lymphoma that has spread to the skin. The main focus is on safety and whether the device can be retrieved with enough usable tissue for analysis.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: a microdevice that releases up to 19 drugs directly into a cancerous skin lesion to test which drugs are most effective
What this could lead to: If successful, this microdevice could help doctors quickly identify the most effective drugs for each patient's lymphoma, personalizing treatment and avoiding ineffective therapies.
What could go wrong: This is a very early pilot study with only 20 participants, focused on safety and feasibility. The device may cause side effects or fail to provide useful results.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CUTANEOUS T-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

mature T-cell and NK-cell non-Hodgkin lymphoma primary cutaneous T-cell non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CUTANEOUS T-CELL LYMPHOMA PERIPHERAL T-CELL LYMPHOMA

Contacts and locations

Locations

Dana Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02115, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.